Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
Date:11/8/2010

at September 30, 2010, as compared to $206.8 million at December 31, 2009.  The decrease in cash, cash equivalents and available-for-sale securities of $48.6 million is primarily due to cash used in operations and other net cash uses offset by proceeds of $2.4 million from the exercise of common stock options and ESPP purchases.

Qnexa Regulatory UpdateOn October 28, 2010, we received a Complete Response Letter (CRL) from the FDA regarding the Qnexa NDA.  The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.  At the present time, we are preparing a written response to the FDA's requests for information in the CRL.

"As demonstrated by the results of the two-year SEQUEL study, Qnexa patients continue to see weight loss greater than 10%.  We received the Qnexa CRL on October 28, 2010.  In response to the FDA's requests, we are working to submit the final study report from SEQUEL and address their requests in a written response to the CRL," stated Leland Wilson, chief executive officer of VIVUS. "In addition to the release of the SEQUEL data, in the third quarter of 2010 we announced the sale of MUSE to Meda.  This transaction closed on November 5, 2010.  The MUSE transaction marks the end of an era and I wish to thank the hundreds of employees that have been involved in the MUSE business since its inception and approval in 1996. The balance sheet remains strong and through the remainder of 2010 we are focused on the written response to the CRL for Qnexa, the filing for approval of Qnexa in the European Union and additional phase 3 trial results from avanafil."

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, Qnexa(R), completed phase 3 clinical trials for the treatment of obesity and an NDA was filed and accepted by the F
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... Oil Market by Extraction type (SFE, Cold Pressed, ... Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - ... MarketsandMarkets, defines and segments the Amaranth Seed Oil ... market size in terms of value. The Amaranth ...
(Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... (NASDAQ: IPHS ), the leading North American ... pharmaceutical, oral care and industrial end markets, today announced ... completed the acquisition of Kelatron Corporation. Kelatron ... of bioactive mineral nutrients. For over 30 years, the ...
... Filtrona Porous Technologies, a developer and manufacturer of custom ... will introduce a new range of hydrophilic, polyurethane foams ... COMPAMED trade fair in Dusseldorf, Germany from 16 to ... New innovations to be featured at ...
Cached Medicine Technology:Innophos Holdings, Inc. Announces Acquisition of Kelatron Corporation 2Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair 2
(Date:9/1/2014)... 01, 2014 An operating theatre or ... for performing surgical operations. An operating room comprises a ... booms, operating room lights, imaging displays as well as ... by Transparency Market Research, a U.S.-based market research firm, ... USD 4.5 billion by 2019. , According to ...
(Date:9/1/2014)... "Women struggle with weight gain typically associated to ... early as 15, if not earlier. Women therefore ... downs of hormone related weight gain. The battle ... to rage against the hidden and ever-present hormones which ... begin to face menopause and related changes, these hormonal ...
(Date:9/1/2014)... By Dennis Thompson ... -- An experimental Ebola drug previously given to two American ... the deadly virus in laboratory tests, researchers report. The ... it, even if they didn,t get the medication until five ... cases of Ebola who were days or even hours away ...
(Date:9/1/2014)... atrial fibrillation (AF) doubles the risk of stroke compared ... 6 000 patients presented at ESC Congress today by ... a simple clinical assessment of the type of AF ... Ischaemic stroke is the second cause of death in ... many more disabled patients each year. Annual direct health ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The National ... to announce that Dawn Bazarko, DNP, MPH, RN, and ... of the American Academy of Nursing. They will be ... RN-BC, CCM, FACHE, whose induction we reported last May. ... 18, 2014, during the 2014 American Academy of Nursing ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4
... go indoors, , , SATURDAY, July 12 (HealthDay News) -- Summer ... so it is also the time for them to be ... is, ,When thunder roars, go indoors," Mary Ann Cooper, director ... Illinois at Chicago, said in a prepared statement. "Decisions about ...
... Emageon Inc.,(Nasdaq: EMAG ), a leader ... networks and imaging facilities,announced today that the Strategic ... Jefferies and Company as Lead Advisor and SunTrust,Robinson ... it evaluates all,strategic options available to the company., ...
... MANHATTAN BEACH, Calif., July 11 A,democratic process involving ... July 14 with hearings to determine the best way ... have the greatest strength,to win for their families and ... step in a thorough, open, and democratic,discussion to make ...
... $500 million in cuts, WASHINGTON, July 11 ... and pay more out of pocket,for health care, while ... legislation approved this week by the U.S. Congress., ... from the,Medicare Advantage program over a five-year period, including ...
... Texas, July 11 Abuelo,s restaurants today,released the ... been linked to consumption of certain raw jalapeno ... recommendation of the Centers for Disease Control (CDC),Abuelo,s ... our recipes and,plate presentations at this time. We ...
... In New York, the majority of Medicaid LTC Funds ... A new report by AARP,s,Public Policy Institute finds mixed ... long-term care (LTC) options under Medicaid.,According to the report, ... Medicaid LTC dollars for older people providing home and ...
Cached Medicine News:Health News:Summer Is Peak Time for Lightning Strikes 2Health News:Florida Seniors' Medicare Advantage Benefits at Risk 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 3
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Medicine Products: